Phase II Study of Pegylated Arginine Deiminase for Nonresectable and Metastatic Hepatocellular Carcinoma.

Trial Profile

Phase II Study of Pegylated Arginine Deiminase for Nonresectable and Metastatic Hepatocellular Carcinoma.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Apr 2010

At a glance

  • Drugs Pegargiminase (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Sponsors Polaris Pharmaceuticals
  • Most Recent Events

    • 15 Apr 2010 New trial record
    • 29 Mar 2010 Results published in the Journal of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top